ArticleJournal of medical biochemistry2025
Early detection of digestive system cancers: Insights from enzymatic and non-enzymatic tumour markers.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomarkers of Cancer Metabolism and Therapeutic Response.Cancer treatment and research · 2026Review
- Evaluation of the vascular remodeling markers elastin, vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor receptor 2 (VEGFR2), and nitric oxide in patients with varicose veins.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Digestive system cancer is a silent yet dangerous disease and represents a major cause of death worldwide. Among these cancers, colon cancer is the second leading cause of cancer-related deaths globally. This study aimed to detect malignant cells early by analyzing biochemical indicators associated with the transformation of digestive cancer cells. Tumour markers, primarily proteins associated with malignant cells, may play a role in preventing the spread and progression of the disease. Methods: In this study, the tumour markers analyzed included carcinoembryonic antigen (CEA), a-enolase (ENO1), a-fetoprotein (AFP), and calprotectin (CP) to detect digestive system cancer. These markers were measured in serum samples from sixty patients with digestive system cancer (the patient group) and sixty healthy individuals (the control group). Results: The results revealed highly significant changes (p-value <0.00001) in the levels of CEA (56.698±44.558 ng/mL), ENO1 (51.784±10.395 ng/mL), AFP (116.275±38.956 ng/mL), and CP (287.425±33.181 ng/mL) in the cancerous group compared to the control group, suggesting their potential utility in early diagnosis. Furthermore, significant differences (p-value <0.05) in liver enzymes and body mass index (BMI) provided additional evidence of pathological changes. Conclusions: The biomarkers investigated in this study demonstrate promising potential for early diagnosis while contributing to a deeper understanding of the biological mechanisms underlying digestive system cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.